menu
    • menu
    [{"orgOrder":0,"company":"Genelux","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Genelux \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Not Applicable"},{"orgOrder":0,"company":"Genelux","sponsor":"Woodward Diversified Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Genelux \/ Woodward Diversified Capital","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Woodward Diversified Capital"},{"orgOrder":0,"company":"Genelux","sponsor":"ELIAS Animal Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"V-VET1","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Genelux \/ ELIAS Animal Health","highestDevelopmentStatusID":"6","companyTruncated":"Genelux \/ ELIAS Animal Health"},{"orgOrder":0,"company":"Genelux","sponsor":"GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ GOG Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ GOG Foundation"},{"orgOrder":0,"company":"Genelux","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Benchmark Company"},{"orgOrder":0,"company":"Genelux","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"Bevacizumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Benchmark Company"},{"orgOrder":0,"company":"Genelux","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Olvimulogene Nanivacirepvec","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Not Applicable"},{"orgOrder":0,"company":"Genelux","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Genelux \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Guggenheim Securities"},{"orgOrder":0,"company":"Genelux","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Genelux \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Guggenheim Securities"},{"orgOrder":0,"company":"Genelux","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Genelux \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genelux \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Genelux

    Menu

    Genelux

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Cisplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genelux Doses First Patient with Olvi-Vec in Phase 2 NSCLC Trial

                            Details : Olvi-Vec is a proprietary, modified oncolytic vaccinia virus, a stable DNA virus with a large engineering capacity. Genelux is developing Olvi-Vec in patients with advanced or metastatic NSCLC.

                            Brand Name : Olvi-Vec

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 22, 2024

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Cisplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Guggenheim Securities

                            Deal Size : $27.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Genelux Corporation Announces Pricing of $27.5 Million Underwritten Offering

                            Details : Proceeds will be used in the development of Olvi-Vec (olvimulogene nanivacirepvec), which is being evaluated in the late-stage clinical trial for the treatment of platinum-resistant ovarian cancer.

                            Brand Name : Olvi-Vec

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 24, 2024

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Guggenheim Securities

                            Deal Size : $27.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Guggenheim Securities

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

                            Details : Proceeds will be used in the development of Olvi-Vec (olvimulogene nanivacirepvec), which is being evaluated in the late-stage clinical trial for the treatment of platinum-resistant ovarian cancer.

                            Brand Name : Olvi-Vec

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 23, 2024

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Guggenheim Securities

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian ...

                            Details : Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in Phase 3 clinical trials for the treatment of platinum resistant/refractory ovarian cancer.

                            Brand Name : Olvi-Vec

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 27, 2023

                            Lead Product(s) : Olvimulogene Nanivacirepvec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Bevacizumab,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Benchmark Company

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Genelux Corporation Announces $18 Million Private Placement

                            Details : Genelux will use the net proceeds for advancement of clinical programs, including the Phase 3 registrational trial of Olvi-Vec (olvimulogene nanivacirepvec), a proprietary, non-pathogenic oncolytic vaccinia virus, in patients with platinum-resistant/refr...

                            Brand Name : Olvi-Vec

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 12, 2023

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Bevacizumab,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Benchmark Company

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Benchmark Company

                            Deal Size : $33.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Genelux Corporation Announces $33 Million Private Placement

                            Details : The proceeds will advance clinical programs, including Phase 3 of Olvi-Vec (olvimulogene nanivacirepvec), a proprietary, modified strain of the VACV, a stable DNA virus with a large engineering capacity, in patients with platinum resistant/refractory ova...

                            Brand Name : Olvi-Vec

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 15, 2023

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Carboplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Benchmark Company

                            Deal Size : $33.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : GOG Foundation

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resis...

                            Details : Olvimulogene Nanivacirepvec (olvi-vec) is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and therapeutic potential.

                            Brand Name : Olvi-Vec

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 21, 2022

                            Lead Product(s) : Olvimulogene Nanivacirepvec,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : GOG Foundation

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : V-VET1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : ELIAS Animal Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Genelux Announces Exclusive Out-Licensing Agreement with ELIAS Animal Health for V-VET1, a Proprietary Oncolyt...

                            Details : ELIAS Animal Health plans clinical trials to evaluate and develop V-VET1 as a potential new immunotherapy option for veterinary oncologists. Under the terms of the agreement, Genelux will receive an upfront payment, development and milestones, and royalt...

                            Brand Name : V-VET1

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 18, 2021

                            Lead Product(s) : V-VET1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : ELIAS Animal Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene nanivacirepvec,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Woodward Diversified Capital

                            Deal Size : $20.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Genelux Announces Closing of a Strategic Financing Transaction

                            Details : The Company intends to use the proceeds from the financing primarily to finalize preparations for and initiate its planned Phase 3 trial of Olvi-Vec in platinum refractory/resistant ovarian cancer.

                            Brand Name : Olvi-Vec

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 25, 2020

                            Lead Product(s) : Olvimulogene nanivacirepvec,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Woodward Diversified Capital

                            Deal Size : $20.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Genelux

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olvimulogene nanivacirepvec,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genelux to Present Data from Phase 2 Trial of Olvi-Vec in Heavily Pre-treated Platinum-Resistant/Refractory Ov...

                            Details : Treatment with olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy shows promising overall survival benefit in this heavily pretreated late-stage patient population.

                            Brand Name : Olvi-Vec

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 16, 2020

                            Lead Product(s) : Olvimulogene nanivacirepvec,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth